Contacts. Labcorp Contacts: Media: Rachael Valdez – 336-436-8263 Media@Labcorp.com Investors: Chas Cook – 336-436-5076 Investor@Labcorp.com ...

Drug development revenue for the quarter was $1.4 billion, a 2.9% decrease compared to second quarter of last year. The company attributed the lower revenue to a decrease in Covid-19 testing.

Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of ...

LH announced that it is pursuing a tax-free spinoff of its Drug Development segment. Our downside case is roughly $230 to $240 assuming earnings remain in line with estimates.

Laboratory Corp of America Holdings missed estimates for quarterly profit on Tuesday, as its drug development unit struggled against curbs on animal imports, while a sharp fall in sales of COVID ...

On July 28, 2022, Labcorp (NYSE: LH, $257.94; Market Capitalization: $23.3 billion), a leading global life sciences company, announced that its Board of Directors authorized a plan to spin-off ...

The logo for Labcorp, Laboratory Corporation of America, a life sciences company is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., June 22, 2023.

Labcorp (NYSE: LH), a leading global life sciences company, today announced that Thomas (Tom) Pike will join Labcorp as president and chief executive ...

Flow cytometry is a powerful, emerging technology that can help medical professionals better understand disease, according to Dr. Bill Hanlon, chief scientific officer of Labcorp Drug Development ...

July 28 (Reuters) - Diagnostics company Labcorp LH.N plans to spin off its unit focused on clinical drug trials, the Wall Street Journal reported on Thursday, citing people familiar with the matter.